Age-stratified phase I trial of a combination of bortezomib, gemcitabine, and liposomal doxorubicin in patients with advanced malignancies

被引：0
|
作者：
G. S. Falchook
M. Duvic
D. S. Hong
J. Wheler
A. Naing
J. Lim
R. Kurzrock
机构：
[1] The University of Texas MD Anderson Cancer Center,Division of Cancer Medicine, Department of Investigational Cancer Therapeutics (Phase I Clinical Trials Program)
[2] The University of Texas MD Anderson Cancer Center,Unit 455
来源：
Cancer Chemotherapy and Pharmacology | 2012年 / 69卷
关键词：
Bortezomib; Gemcitabine; Liposomal doxorubicin; Cutaneous T-cell lymphoma; Small cell carcinoma; Phase I;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：1117 / 1126
页数：9
相关论文
共 50 条
  • [31] Phase I combination trial of gemcitabine, paclitaxel, and carboplatin in patients with advanced malignancy
    Flaherty, KT
    Stevenson, JP
    Hahn, SM
    Redlinger, M
    O'Dwyer, PJ
    CANCER CHEMOTHERAPY AND PHARMACOLOGY, 2003, 52 (03) : 217 - 222
  • [32] Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Shaji K. Kumar
    James Jett
    Randolph Marks
    Ronald Richardson
    Fernando Quevedo
    Timothy Moynihan
    Gary Croghan
    Svetomir N. Markovic
    Keith C. Bible
    Rui Qin
    Angelina Tan
    Julian Molina
    Scott H. Kaufmann
    Charles Erlichman
    Alex A. Adjei
    Investigational New Drugs, 2013, 31 : 1201 - 1206
  • [33] Phase I trial of oblimersen (GenasenseA®) and gemcitabine in refractory and advanced malignancies
    Galatin, Peter S.
    Advani, Ranjana H.
    Fisher, George A.
    Francisco, Brian
    Julian, Thomas
    Losa, Raquel
    Sierra, Marta I.
    Sikic, Branimir I.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (05) : 971 - 977
  • [34] Phase I study of amifostine as a cytoprotector of the gemcitabine/cisplatin combination in patients with advanced solid malignancies
    Haigentz, M
    Kim, M
    Sorich, J
    Lee, J
    Hochster, H
    Macapinlac, M
    Mirchandani, D
    Sewak, S
    Pavlick, A
    Volm, M
    Hamilton, A
    Muggia, FM
    ANTI-CANCER DRUGS, 2003, 14 (04) : 321 - 326
  • [35] Phase 1 study of sorafenib in combination with bortezomib in patients with advanced malignancies
    Kumar, Shaji K.
    Jett, James
    Marks, Randolph
    Richardson, Ronald
    Quevedo, Fernando
    Moynihan, Timothy
    Croghan, Gary
    Markovic, Svetomir N.
    Bible, Keith C.
    Qin, Rui
    Tan, Angelina
    Molina, Julian
    Kaufmann, Scott H.
    Erlichman, Charles
    Adjei, Alex A.
    INVESTIGATIONAL NEW DRUGS, 2013, 31 (05) : 1201 - 1206
  • [36] Phase I trial of oblimersen (Genasense®) and gemcitabine in refractory and advanced malignancies
    Peter S. Galatin
    Ranjana H. Advani
    George A. Fisher
    Brian Francisco
    Thomas Julian
    Raquel Losa
    Marta I. Sierra
    Branimir I. Sikic
    Investigational New Drugs, 2011, 29 : 971 - 977
  • [37] Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Traynor, Anne M.
    Thomas, James P.
    Ramanathan, Ramesh K.
    Mody, Tarak D.
    Alberti, Dona
    Wilding, George
    Bailey, Howard H.
    INVESTIGATIONAL NEW DRUGS, 2011, 29 (02) : 316 - 322
  • [38] Phase I trial of motexafin gadolinium and doxorubicin in the treatment of advanced malignancies
    Anne M. Traynor
    James P. Thomas
    Ramesh K. Ramanathan
    Tarak D. Mody
    Dona Alberti
    George Wilding
    Howard H. Bailey
    Investigational New Drugs, 2011, 29 : 316 - 322
  • [39] Gemcitabine and doxorubicin for the treatment of patients with advanced hepatocellular carcinoma: a phase I-II trial
    Yang, TS
    Wang, CH
    Hsieh, RK
    Chen, JS
    Fung, MC
    ANNALS OF ONCOLOGY, 2002, 13 (11) : 1771 - 1778
  • [40] Phase I and pharmacological trial of lapatinib in combination with gemcitabine in patients with advanced breast cancer
    van der Noll, R.
    Smit, W. M.
    Wymenga, A. N. M.
    Boss, D. S.
    Grob, M.
    Huitema, A. D. R.
    Rosing, H.
    Tibben, M. M.
    Keessen, M.
    Rehorst, H.
    Beijnen, J. H.
    Schellens, J. H. M.
    INVESTIGATIONAL NEW DRUGS, 2015, 33 (06) : 1197 - 1205
12345